A 12 week, randomized, double-blind, placebo-controlled clinical trial for the evaluation of the efficacy and safety of TabetriTM on atopic dermatitis in childre
- Conditions
- Diseases of the skin and subcutaneous tissue
- Registration Number
- KCT0002640
- Lead Sponsor
- utri Biotech
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
1) Patients who agree to participate in this experiment and write consent including the subject and the parent (or legal representative)
2) Patients who aged 4~12 years of both sexes
3) Patients who have had intermittent or persistent atopic dermatitis symptoms for more than 6 months
4) Patients with mide to moderate atopic dermatitis symptoms (SCORing of Atopic Dermatitis, SCORAD index range from 20 to 50)
1) Pateints who had severe skin disease, systemic disease
2) Patients who had prior treatments associated with atopic dermatitis, including systemic antibiotics, corticosteroids, anti-histamines, immunosuppressant within 4 weeks prior to the study
3) Patients who administered medicine, herbal medicine, any health functional supplements to improve atopic dermatitis within 1 week
4) Patients who had phototherapy within 4 weeks prior to the study
5) Patients who plan to participate in another human body test during this experiment
6) Patients who participated in another human body test before this experiment within 4 weeks
7) Patients who is deemed by the examiner to be inappropriate for this experiment
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method SCORAD total score
- Secondary Outcome Measures
Name Time Method SCORing of Atopic Dermatitis objective score;SCORing of Atopic Dermatitis subjective score;Investigator’s Global Assessment;Eosinophil count, inflammatory biomarker;Usage of topical steroids (Percentage and dose)